Frankfurt
05.03.26 | 08:00
4,100 Euro
+3,02 % +0,120
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Board Member Of Lifevantage Makes $152K Buy | 1 | Benzinga.com | ||
| Mo | Dividendenbekanntmachungen (02.03.2026) | 9.414 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1523 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1861 EUR ALLSTATE... ► Artikel lesen | |
| LIFEVANTAGE Aktie jetzt für 0€ handeln | |||||
| 25.02. | LifeVantage kündigt CEO-Wechsel zum April 2026 an | 2 | Direct Selling Magazine | ||
| 19.02. | LifeVantage meldet Umsatzcrash in Höhe von 27,8 Prozent | 1 | Direct Selling Magazine | ||
| 05.02. | LifeVantage outlines $185M-$200M revenue target and new $60M buyback amid GLP-1 headwinds and LoveBiome integration | 1 | Seeking Alpha | ||
| 04.02. | LifeVantage Q2 2026: Gewinnziel erreicht, Umsatzprognose verfehlt | 2 | Investing.com Deutsch | ||
| 04.02. | LifeVantage CEO Steve Fife to retire in April | 1 | Seeking Alpha | ||
| 04.02. | LifeVantage CEO Steve Fife to retire in April after nine-year tenure | 3 | Investing.com | ||
| 04.02. | LifeVantage announces $0.045 quarterly dividend payable in March | 1 | Investing.com | ||
| 04.02. | LifeVantage Non-GAAP EPS of $0.15 in-line, revenue of $48.9M misses by $5.5M | 2 | Seeking Alpha | ||
| 04.02. | LifeVantage Corporation: LifeVantage Declares Quarterly Dividend | 1 | GlobeNewswire (USA) | ||
| 04.02. | LifeVantage Corporation: LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan | 382 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level... ► Artikel lesen | |
| 04.02. | Lifevantage Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | Lifevantage Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 04.02. | LifeVantage Corporation: LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 | 1.743 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| 21.01. | LifeVantage Corporation: LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.01. | LifeVantage Corporation: LifeVantage Kicked Off 2026 With Global Kickoff, a Virtual Event Showcasing Innovation and Integration | 1 | GlobeNewswire (USA) | ||
| 07.01. | LifeVantage appoints Mike Edwards as chief technology officer | 1 | Investing.com | ||
| 07.01. | LifeVantage Corporation: LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation | 223 | GlobeNewswire (Europe) | SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| 10.12.25 | LifeVantage Corporation: LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025 | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 124,76 | -0,24 % | Gilead Sciences (GILD): Spannendes Chartbild - 150-USD-Trigger im Visier! | Vom HIV-Spezialisten zum Onkologie-Powerhouse! Rückblick Seit Anfang des Jahres befand sich die Aktie von Gilead Sciences in einem starken Aufwärtsimpuls, der sie von rund 122 US-Dollar bis auf ein... ► Artikel lesen | |
| ABBVIE | 200,00 | -0,25 % | AbbVie Reports Positive Phase 3 Results For Risankizumab In Crohn's Disease | WASHINGTON (dpa-AFX) - AbbVie (ABBV) on Monday announced positive results from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab in moderately to severely active Crohn's disease.... ► Artikel lesen | |
| ELI LILLY | 845,10 | -0,21 % | Ausschreibung KONKRET-Preis 2026: Neues Setting, erhöhtes Preisgeld / Lilly Deutschland Stiftung intensiviert Innovationsförderung in der Gesundheitsversorgung | Bad Homburg (ots) - Mit dem Innovationspreis KONKRET fördert die Lilly Deutschland Stiftung Projekte, die Lücken und Barrieren in der Gesundheitsversorgung adressieren. Aufbauend auf bisherigen Erfolgen... ► Artikel lesen | |
| MERCK & CO | 99,70 | -0,30 % | MERCK & CO INC: Schwäche im Fokus, Chance im Detail | ||
| TEVA | 27,300 | -0,36 % | Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) and funds managed by Blackstone Life Sciences announced a $400 million strategic funding... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 397,10 | -0,05 % | Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on JOURNAVX That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures | -Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain... ► Artikel lesen | |
| EYEPOINT | 13,845 | +1,88 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| INCYTE | 84,34 | +0,55 % | Incyte auf der TD Cowen Konferenz: Strategisches Wachstum jenseits von Jakafi | ||
| ORGANIGRAM GLOBAL | 1,230 | -2,38 % | Organigram Global Inc. (OGI) Sees C$4 Target on Improved Outlook | ||
| IONIS PHARMACEUTICALS | 64,44 | -0,49 % | Ionis Pharmaceuticals: Einblicke in die Wachstumsstrategie auf der TD Cowen Konferenz | ||
| QUANTUM BIOPHARMA | 3,360 | +7,69 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 63,50 | +1,60 % | Nektar Therapeutics auf der TD Cowen Konferenz: Fokus auf Immunologie | ||
| AMARIN | 12,100 | -0,82 % | AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know | ||
| MEDPACE | 406,20 | +0,42 % | 7 Analysts Assess Medpace Holdings: What You Need To Know | ||
| LIGAND PHARMACEUTICALS | 180,00 | +1,12 % | Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts |
LIFEVANTAGE CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +3,02 % bei einem Aktienkurs von 4,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIFEVANTAGE CORPORATION finden Sie auf Wallstreet Online.